Zanzalintinib (XL092)

The pivotal trial supports an overall-survival benefit for zanzalintinib plus atezolizumab versus regorafenib in its intention-to-treat population, with a higher frequency of grade 3 or higher treatment-related adverse events. The later analysis without active liver metastases did not meet statistical significance. Zanzalintinib remains investigational in the cited regulatory evidence. The updated FDA target action date is March 3, 2027; that date is not an approval or a confirmed commercial launch date.